These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37059263)

  • 21. An enhanced mixture method for constructing gatekeeping procedures in clinical trials.
    Kordzakhia G; Brechenmacher T; Ishida E; Dmitrienko A; Zheng WW; Li DF
    J Biopharm Stat; 2018; 28(1):113-128. PubMed ID: 29239689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Controlling the false discovery rate with constraints: the Newman-Keuls test revisited.
    Shaffer JP
    Biom J; 2007 Feb; 49(1):136-43. PubMed ID: 17342955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approaches to multiplicity in publicly funded pragmatic randomised controlled trials: a survey of clinical trials units and a rapid review of published trials.
    Pike K; Reeves BC; Rogers CA
    BMC Med Res Methodol; 2022 Feb; 22(1):39. PubMed ID: 35125091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Power and sample size calculation for microarray studies.
    Jung SH; Young SS
    J Biopharm Stat; 2012; 22(1):30-42. PubMed ID: 22204525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modeling.
    Yamaguchi Y; Sugitani T; Yoshida S; Maruo K
    Pharm Stat; 2022 Nov; 21(6):1309-1323. PubMed ID: 35708144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An efficient and flexible multiplicity adjustment for chi-square endpoints.
    Wagler A; McCann M
    Math Biosci Eng; 2021 Jun; 18(5):4971-4986. PubMed ID: 34517473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classes of Multiple Decision Functions Strongly Controlling FWER and FDR.
    Peña EA; Habiger JD; Wu W
    Metrika; 2015 Jul; 78(5):563-595. PubMed ID: 26166847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analyzing multiple endpoints in a confirmatory randomized clinical trial-an approach that addresses stratification, missing values, baseline imbalance and multiplicity for strictly ordinal outcomes.
    Sun H; Kawaguchi A; Koch G
    Pharm Stat; 2017 Mar; 16(2):157-166. PubMed ID: 28074600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of Design and Analysis of Ophthalmic Randomized Controlled Trials: A Review of Ophthalmic Papers 2020-2021.
    Dong R; Ying GS
    Ophthalmol Sci; 2023 Jun; 3(2):100266. PubMed ID: 36798523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stepwise progressive parametric multiple testing procedure with correlated normal test statistics.
    Deng X; Chang M
    J Biopharm Stat; 2020 May; 30(3):550-563. PubMed ID: 32191556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):169-188. PubMed ID: 29125802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
    Harden M; Friede T
    Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug development.
    Li W; Zhou H; Jia C; Sun L
    Contemp Clin Trials; 2022 Aug; 119():106846. PubMed ID: 35803494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. POWER-ENHANCED MULTIPLE DECISION FUNCTIONS CONTROLLING FAMILY-WISE ERROR AND FALSE DISCOVERY RATES.
    Peña EA; Habiger JD; Wu W
    Ann Stat; 2011 Feb; 39(1):556-583. PubMed ID: 25018568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weighted false discovery rate controlling procedures for clinical trials.
    Benjamini Y; Cohen R
    Biostatistics; 2017 Jan; 18(1):91-104. PubMed ID: 27445132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resampling-based stepwise multiple testing procedures with applications to clinical trial data.
    He J; Li F; Gao Y; Rothmann M
    Pharm Stat; 2021 Mar; 20(2):297-313. PubMed ID: 33103348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculation for simulation-based multiple-testing procedures.
    Bang H; Jung SH; George SL
    J Biopharm Stat; 2005; 15(6):957-67. PubMed ID: 16279354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.